DemeRx

The Week In Psychedelics: Delic Signs $10 Million Merger With Chain Of Ketamine Clinics Atai Subsidiary DemeRx Launches Phase 1/2a Clinical Trial On Ibogaine Small Pharma Completes Phase 1 Trial on DTM For Depression, Moves to Phase 2a MindMed and Liechti Lab Release Research Results...

This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Psilocybin Alpha. In just a couple of years, psychedelics took the world of investing by storm. What in 2019 was merely a buzzword for investors became a full-fledged industry boasting over 25...

Novamind Raises CA$10M, Heads Towards CSE Listing Toronto-based psychedelics company Novamind Ventures announced the closing of a private placement for CA$10 million ($7.6 million). Last week, the company confirmed that it successfully inked a definitive amalgamation agreement with Hinterland...

In 2018, 2.1 million Americans met the diagnostic criteria for opioid use disorder (OUD), with 47,600 people dying from overdoses. Current treatment options for OUD are not only limited, but often carry risk of significant side effects and abuse potential. In response to this huge unmet...